Reported 466,050 shares, down 158,878 (25.4%) from the prior quarter.
Reported value -13.0%; share count -25.4% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2024-06-30 | 11213762 |
| 2024-09-30 | 16234254 |
| 2024-12-31 | 12713642 |
| 2025-03-31 | 13871144 |
| 2025-06-30 | 17659907 |
| 2025-09-30 | 22436828 |
| 2025-12-31 | 24602779 |
| 2026-03-31 | 29295230 |
| 2026-06-30 | 39964146 |
| 2026-09-30 | 34771991 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 466,050 | -158,878 (-25.4%) | 1.84% | $34,771,991 | 2026-11-16 | |
| Q2 2026 | Added | 624,928 | +16,512 (2.7%) | 1.95% | $39,964,146 | 2026-08-07 | |
| Q1 2026 | Added | 608,416 | +11,985 (2.0%) | 1.63% | $29,295,230 | 2026-05-15 | |
| Q4 2025 | Added | 596,431 | +18,609 (3.2%) | 1.35% | $24,602,779 | 2026-02-17 | |
| Q3 2025 | Reduced | 577,822 | -60,411 (-9.5%) | 1.22% | $22,436,828 | 2025-10-16 | |
| Q2 2025 | Added | 638,233 | +13,688 (2.2%) | 0.95% | $17,659,907 | 2025-08-11 | |
| Q1 2025 | Reduced | 624,545 | -18,207 (-2.8%) | 0.82% | $13,871,144 | 2025-05-01 | |
| Q4 2024 | Reduced | 642,752 | -6,878 (-1.1%) | 0.7% | $12,713,642 | 2025-01-31 | |
| Q3 2024 | Added | 649,630 | +49,000 (8.2%) | 0.88% | $16,234,254 | 2024-10-28 | |
| Q2 2024 | New | 600,630 | +600,630 (0.0%) | 0.67% | $11,213,762 | 2024-08-07 |
Who else reported the position
328 managers reported KINIKSA PHARMACEUTICALS INTL for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 7,487,391 | +516,030 | 0.02% | $558,634,260 | 10 qtrs |
| BlackRock Inc | Added | 2,943,674 | +204,059 | < 0.01% | $219,627,516 | 9 qtrs |
| BAKER BROS ADVISORS LP | Unchanged | 2,834,643 | 0 | 1.0% | $211,492,714 | 10 qtrs |
| Rubric Capital Management LP | Reduced | 2,813,469 | -1,186,331 | 1.97% | $209,912,922 | 10 qtrs |
| TANG CAPITAL MANAGEMENT LLC | Unchanged | 2,259,889 | 0 | 7.76% | $168,610,318 | 10 qtrs |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Added | 2,030,666 | +119,331 | < 0.01% | $151,507,990 | 3 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 1,433,679 | +72,839 | < 0.01% | $106,966,790 | 3 qtrs |
| ARROWSTREET CAPITAL LIMITED PARTNERSHIP | Added | 1,093,930 | +136,416 | 0.03% | $81,618,117 | 10 qtrs |
| MORGAN STANLEY | Reduced | 936,373 | -74,770 | < 0.01% | $69,862,871 | 10 qtrs |
| STATE STREET CORPORATION | Added | 926,267 | +222,073 | < 0.01% | $69,108,781 | 10 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- ORD SHS CL A
Voting authority reported
- Sole
- 398,282
- Shared
- 0
- None
- 67,768
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.